AI assistant
Vir Biotechnology, Inc. — Director's Dealing 2019
Oct 11, 2019
32538_dirs_2019-10-10_ef4e9fa4-dba3-4aa6-ba22-fe4dba29dadd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-10
Reporting Person: Pang Phillip (Chief Medical Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 7777 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.86 | 2027-03-09 | Common Stock (103333) | Direct | |
| Stock Option (Right to Buy) | $1.53 | 2028-04-27 | Common Stock (111111) | Direct | |
| Stock Option (Right to Buy) | $1.58 | 2028-07-19 | Common Stock (111111) | Direct | |
| Stock Option (Right to Buy) | $5.18 | 2029-03-11 | Common Stock (111110) | Direct |
Footnotes
F1: 1/4 of the 111,111 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.
F2: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
F3: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
F4: 1/4 of the shares subject to the stock option will vest and become exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.